Success Metrics

Clinical Success Rate
79.2%

Based on 19 completed trials

Completion Rate
79%(19/24)
Active Trials
1(3%)
Results Posted
32%(6 trials)
Terminated
5(14%)

Phase Distribution

Ph phase_2
9
26%
Ph phase_1
6
17%
Ph not_applicable
6
17%
Ph phase_3
4
11%
Ph phase_4
10
29%

Phase Distribution

6

Early Stage

9

Mid Stage

14

Late Stage

Phase Distribution35 total trials
Phase 1Safety & dosage
6(17.1%)
Phase 2Efficacy & side effects
9(25.7%)
Phase 3Large-scale testing
4(11.4%)
Phase 4Post-market surveillance
10(28.6%)
N/ANon-phased studies
6(17.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

73.1%

19 of 26 finished

Non-Completion Rate

26.9%

7 ended early

Currently Active

1

trials recruiting

Total Trials

35

all time

Status Distribution
Active(1)
Completed(19)
Terminated(7)
Other(8)

Detailed Status

Completed19
unknown8
Terminated5
Withdrawn2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
35
Active
1
Success Rate
79.2%
Most Advanced
Phase 4

Trials by Phase

Phase 16 (17.1%)
Phase 29 (25.7%)
Phase 34 (11.4%)
Phase 410 (28.6%)
N/A6 (17.1%)

Trials by Status

unknown823%
recruiting13%
terminated514%
completed1954%
withdrawn26%

Recent Activity

Clinical Trials (35)

Showing 20 of 35 trialsScroll for more
NCT04918719Phase 2

Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke

Completed
NCT07414212Phase 1

Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS)

Recruiting
NCT02569957Phase 2

Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Terminated
NCT05070650Phase 3

Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold

Withdrawn
NCT00558142Phase 4

Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material

Completed
NCT05804123Not Applicable

LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media

Completed
NCT02788292Phase 4

Effect of N-Acetylcysteine on Autologous Fat Graft Survival

Withdrawn
NCT03976973Phase 2

BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei

Unknown
NCT05258682Phase 1

Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease

Unknown
NCT04123405Phase 3

Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis

Completed
NCT04945096Phase 3

Outcomes of Patients After Allo-HSCT With Decitabine and NAC

Unknown
NCT04368598Phase 2

The Combination of High-dose Dexamethasone and Acetylcysteine as the Treatment of Newly-diagnosed ITP

Unknown
NCT03177395Phase 1

PP100-01 (Calmangafodipir) for Overdose of Paracetamol

Completed
NCT02123511Phase 2

Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

Completed
NCT03460808Phase 1

The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Unknown
NCT02159196Not Applicable

Effectiveness of Routine Nebulization of Mucolytics and Bronchodilators During Mechanical Ventilation

Completed
NCT00238173Phase 1

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

Terminated
NCT02818270Not Applicable

Evaluation of Aerosolized Drugs Deposition During Mechanical Ventilation

Completed
NCT02760901Phase 2

Evaluation of the Effect of Acetazolamide, Mannitol and N-acetylcysteine on Cisplatin-Induced Nephrotoxicity

Completed
NCT02882477Phase 2

Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
35